These AIHTA assessments evaluate the efficacy and safety of (new) cancer drugs to facilitate evidence-based decision-making.
Lung cancer screening in risk groups Systematic review(s) of effectiveness and utility (part 1) Costs and budgetary consequences (part 2)
Project leaders: Claudia Wild (part 1), Ingrid Zechmeister-Koss (part 2)
- Thomas Semlitsch (IAVEM) & EUnetHTA partners (IQWIG, potentially others) (part 1)
- Christan Böhler, Sarah Wolf (part 2)
Duration: May 2020 – November 2020
Language: English with German summary
Stereotactic radiotherapy (Cyberknife®), proton beam therapy and irreversible (electroporation Nanoknife®) for localised prostate cancer (PCa): a systematic review
Project team: Louise Schmidt, Pia Lohr
Suggested by: Main Association of the Austrian Social Security Institutions
Duration: February 2018 – June 2018
Language: German (with English summary)
Publication: LBI-HTA Project report No. 107: https://eprints.aihta.at/1165
Health Services Research (HSR) in oncology in a selected indication: Cancer therapies for lung patients
Project team: Nicole Grössmann-Waniek
Support in data evaluation and processing: DexHelpp
Duration: October 2018 – December 2019
Supported by DexHelpp (data-requirements and -acquisition), Nicole Grössmann
Duration: January 2018 – March 2020
Publication: LBI-HTA Project report No. 127: http://eprints.aihta.at/1233
Supported by DexHelpp (data-requirements and -acquisition), Martin Robausch
Duration: January 2018 – December 2019
Grössmann N, Robausch M, Willenbacher W, Wolf S, Simon J, Wild C. “Magnitude of clinical benefit” of solid tumour drugs and their real-world application in the Austrian health care setting. Journal of Cancer Policy. 2020;25:100235.
Clinical benefit of oncology drugs – Contrasting the evidence of clinically relevant endpoints three years after EMA approval
Duration: December 2017 – March 2020
Grössmann N, Robausch M, Rothschedl E, Wild C, Simon J (2019): Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015. European Journal of Cancer. 2020;129:23-31.
Grössmann N, Robausch M, Rosian K, Wild C, Simon J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. European Journal of Cancer 2019; 110:1-7.
Duration: September 2014 - December 2014
Publication: LBI-HTA Project report No. 77: https://eprints.aihta.at/1045
Appraisal of the quality and accuracy of written consumer health information for patients with chronic myeloid leukaemia on treatment-regimens with dasatinib, nilotinib or imatinib
Project team: Katharina Hintringer, Jone Gerdvilate
Duration: April 2011 - February 2012